

General information about company		
Scrip code*	506235	
NSE Symbol*	ALEMBICLTD	
MSEI Symbol*	NOTLISTED	
ISIN*	INE426A01027	
Name of company	Alembic Limited	
Type of company	Main Board	
Class of security	Equity	
Date of start of financial year	01-04-2024	
Date of end of financial year	31-03-2025	
Date of board meeting when results were approved	13-05-2025	
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	02-05-2025	
Description of presentation currency	INR	
Level of rounding	Lakhs	
Reporting Type	Quarterly	
Reporting Quarter	Fourth quarter	
Nature of report standalone or consolidated	Standalone	
Whether results are audited or unaudited for the quarter ended	Audited	
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Audited	
Segment Reporting	Multi segment	
Description of single segment		
Start date and time of board meeting	13-05-2025 16:00	
End date and time of board meeting	13-05-2025 17:15	
Whether cash flow statement is applicable on company	Yes	
Type of cash flow statement	Cash Flow Indirect	
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion	
Whether the company has any related party?	Yes	
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes	
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA	
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA	
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?	No	
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?		
(b) If answer to above question is No, please explain the reason for not complying.		
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?	Yes	
Latest Date on which RPT policy is updated	07-02-2025	
Indicate Company website link for updated RPT policy of the Company	https://www.alembiclimited.com/policy/Related-Party-Transaction-Policy.pdf	
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	No	
No. of times funds raised during the quarter		
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	No	Not Applicable

Financial Results – Ind-AS			
Particulars	3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)	
Date of start of reporting period	01-01-2025	01-04-2024	
Date of end of reporting period	31-03-2025	31-03-2025	
Whether results are audited or unaudited	Audited	Audited	
Nature of report standalone or consolidated	Standalone	Standalone	
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.			
1 Income			
Revenue from operations	5821.64	21435.79	
Other income	278.07	7451.02	
Total income	6099.71	28886.81	
2 Expenses			
(a) Cost of materials consumed	192.36	800.21	
(b) Purchases of stock-in-trade	0	0	
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-2.62	111.38	
(d) Employee benefit expense	649.51	2730.95	
(e) Finance costs	45.46	182.98	
(f) Depreciation, depletion and amortisation expense	265.79	1024.46	
(g) Other Expenses			
1 Cost of Construction	1549.09	6005.35	
2 Other Expenses	832.2	2832.57	
Total other expenses	2381.29	8837.92	
Total expenses	3531.79	13687.9	
3 Total profit before exceptional items and tax	2567.92	15198.91	
4 Exceptional items	0	0	
5 Total profit before tax	2567.92	15198.91	
6 Tax expense			
7 Current tax	315	1675	
8 Deferred tax	-29.91	-670.81	
9 Total tax expenses	285.09	1004.19	
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0	
11 Net Profit Loss for the period from continuing operations	2282.83	14194.72	
12 Profit (loss) from discontinued operations before tax	0	0	
13 Tax expense of discontinued operations	0	0	
14 Net profit (loss) from discontinued operation after tax	0	0	
15 Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0	
16 Total profit (loss) for period	2282.83	14194.72	
Other comprehensive income net of taxes	-2290.21	-3588.73	
18 Total Comprehensive Income for the period	-7.38	10605.99	
19 Total profit or loss, attributable to			
Profit or loss, attributable to owners of parent			
Total profit or loss, attributable to non-controlling interests			
20 Total Comprehensive income for the period attributable to			
Comprehensive income for the period attributable to owners of parent			
Total comprehensive income for the period attributable to owners of parent non-controlling interests			
21 Details of equity share capital			
Paid-up equity share capital	5135.64	5135.64	
Face value of equity share capital	2	2	
22 Reserves excluding revaluation reserve	56249.93		
23 Earnings per share			
i Earnings per equity share for continuing operations			
Basic earnings (loss) per share from continuing operations	0.89	5.53	
Diluted earnings (loss) per share from continuing operations	0.89	5.53	
ii Earnings per equity share for discontinued operations			
Basic earnings (loss) per share from discontinued operations	0	0	
Diluted earnings (loss) per share from discontinued operations	0	0	
iii Earnings per equity share (for continuing and discontinued operations)			
Basic earnings (loss) per share from continuing and discontinued operations	0.89	5.53	
Diluted earnings (loss) per share from continuing and discontinued operations	0.89	5.53	
24 Debt equity ratio			Textual Information(1)
25 Debt service coverage ratio			Textual Information(2)
26 Interest service coverage ratio			Textual Information(3)
27 Disclosure of notes on financial results	Textual Information(4)		

Text Block	
Textual Information(4)	<p>Notes</p> <p>1. The above results have been audited by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company.</p> <p>2. The Board has recommended Dividend on equity shares at Rs 2.40 per share (face value Rs. 2/- each) i.e 120% for the year ended on 31st March, 2025 (Previous year Rs. 2.40 per share i.e 120%).</p> <p>3. The previous quarter's year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter year.</p> <p>4. The figures for the quarter ended 31st March, 2025 and corresponding quarter ended 31st March, 2024 are the balancing figures between the audited figures in respect of full financial year and year to date figures upto third quarter of the respective financial years which were subject to limited review.</p>

Statement of Asset and Liabilities		
Particulars	Year ended (dd-mm-yyyy)	
	Date of start of reporting period	01-04-2024
	Date of end of reporting period	31-03-2025
	Whether results are audited or unaudited	Audited
	Nature of report standalone or consolidated	Standalone
Assets		
1 Non-current assets		
Property, plant and equipment		13533.4
Capital work-in-progress		0
Investment property		27106.63
Goodwill		0
Other intangible assets		0
Intangible assets under development		0
Biological assets other than bearer plants		0
Investments accounted for using equity method		0
Non-current financial assets		
Non-current investments		36410.51
Trade receivables, non-current		0
Loans, non-current		0
Other non-current financial assets		801.93
Total non-current financial assets		37212.44
Deferred tax assets (net)		0
Other non-current assets		3500
Total non-current assets		81352.47
2 Current assets		
Inventories		9938.7
Current financial asset		
Current investments		4955.88
Trade receivables, current		2789
Cash and cash equivalents		253.04
Bank balance other than cash and cash equivalents		165.87
Loans, current		0
Other current financial assets		318.65
Total current financial assets		8482.44
Current tax assets (net)		0
Other current assets		1209.65
Total current assets		19630.79
3 Non-current assets classified as held for sale		0
4 Regulatory deferral account debit balances and related deferred tax Assets		0
Total assets		100983.26
Total current assets	19630.79	
3 Non-current assets classified as held for sale		0
4 Regulatory deferral account debit balances and related deferred tax Assets		0
Total assets	100983.26	
Equity and liabilities		
1 Equity		
Equity attributable to owners of parent		
Equity share capital		5135.64
Other equity		80183.49
Total equity attributable to owners of parent	85319.13	
Non controlling interest		
Total equity	85319.13	
2 Liabilities		
Non-current liabilities		
Non-current financial liabilities		
Borrowings, non-current		1066.53
Trade Payables, non-current		
(A) Total outstanding dues of micro enterprises and small enterprises		0
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises		0
Total Trade payable	0	
Other non-current financial liabilities		691.22
Total non-current financial liabilities	1757.75	
Provisions, non-current		244.13
Deferred tax liabilities (net)		2833.93
Deferred government grants, Non-current		0
Other non-current liabilities		0
Total non-current liabilities	4835.81	
Current liabilities		
Current financial liabilities		

	Borrowings, current	378.2
	Trade Payables, current	
	(A) Total outstanding dues of micro enterprises and small enterprises	520.9
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	2236.96
	Total Trade payable	2757.86
	Other current financial liabilities	607.24
	Total current financial liabilities	3743.3
	Other current liabilities	4253.08
	Provisions, current	2151.55
	Current tax liabilities (Net)	680.39
	Deferred government grants, Current	0
	Total current liabilities	10828.32
3	Liabilities directly associated with assets in disposal group classified as held for sale	0
4	Regulatory deferral account credit balances and related deferred tax liability	0
	Total liabilities	15664.13
	Total equity and liabilities	100983.26
	Disclosure of notes on assets and liabilities	Textual Information(I)

Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results		
Particulars	3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period	01-01-2025	01-04-2024
Date of end of reporting period	31-03-2025	31-03-2025
Whether results are audited or unaudited	Audited	Audited
Nature of report standalone or consolidated	Standalone	Standalone
1 Segment Revenue (Income)		
(net sale/income from each segment should be disclosed)		
1 Active Pharmaceutical Ingredients Business	778.43	3221.48
2 Real Estate Business	5043.21	18214.31
Total Segment Revenue	5821.64	21435.79
Less: Inter segment revenue	0	0
Revenue from operations	5821.64	21435.79
2 Segment Result		
Profit (+) / Loss (-) before tax and interest from each segment		
1 Active Pharmaceutical Ingredients Business	187.86	472.85
2 Real Estate Business	2422.72	8390.15
Total Profit before tax	2610.58	8863
i. Finance cost	45.46	182.98
ii. Other Unallocable Expenditure net off Unallocable income	-2.81	-6518.89
Profit before tax	2567.93	15198.91
3 (Segment Asset - Segment Liabilities)		
Segment Asset		
1 Active Pharmaceutical Ingredients Business	18721.7	18721.7
2 Real Estate Business	43080.38	43080.38
Total Segment Asset	61802.08	61802.08
Un-allocable Assets	39181.18	39181.18
Net Segment Asset	100983.26	100983.26
4 Segment Liabilities		
Segment Liabilities		
1 Active Pharmaceutical Ingredients Business	3127.69	3127.69
2 Real Estate Business	9022.12	9022.12
Total Segment Liabilities	12149.81	12149.81
Un-allocable Liabilities	3514.32	3514.32
Net Segment Liabilities	15664.13	15664.13
Disclosure of notes on segments		

Other Comprehensive Income		
	Date of start of reporting period	01-01-202501-04-2024
	Date of end of reporting period	31-03-202531-03-2025
	Whether results are audited or unaudited	AuditedAudited
	Nature of report standalone or consolidated	StandaloneStandalone
	Other comprehensive income [Abstract]	
1	Amount of items that will not be reclassified to profit and loss	
1	Amount of items that will not be reclassified to profit and loss	-2672.76-3457.04
	Total Amount of items that will not be reclassified to profit and loss	-2672.76-3457.04
2	Income tax relating to items that will not be reclassified to profit or loss	-382.55131.69
3	Amount of items that will be reclassified to profit and loss	
	Total Amount of items that will be reclassified to profit and loss	
4	Income tax relating to items that will be reclassified to profit or loss	0.000.00
5	Total Other comprehensive income	-2290.21-3588.73

Cash flow statement, indirect		
Particulars		Year ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2024
Date of end of reporting period		31-03-2025
Whether results are audited or unaudited		Audited
Nature of report standalone or consolidated		Standalone
Part I	Blue color marked fields are non-mandatory.	
1	Statement of cash flows	
	Cash flows from used in operating activities	
	Profit before tax	15198.91
2	Adjustments for reconcile profit (loss)	
	Adjustments for finance costs	182.98
	Adjustments for decrease (increase) in inventories	-678.28
	Adjustments for decrease (increase) in trade receivables, current	-1049.38
	Adjustments for decrease (increase) in trade receivables, non-current	0
	Adjustments for decrease (increase) in other current assets	-429.64
	Adjustments for decrease (increase) in other non-current assets	0
	Adjustments for other financial assets, non-current	262.53
	Adjustments for other financial assets, current	-51.85
	Adjustments for other bank balances	0
	Adjustments for increase (decrease) in trade payables, current	-283.05
	Adjustments for increase (decrease) in trade payables, non-current	0
	Adjustments for increase (decrease) in other current liabilities	1839.96
	Adjustments for increase (decrease) in other non-current liabilities	0
	Adjustments for depreciation and amortisation expense	1024.46
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	0
	Adjustments for provisions, current	36.48
	Adjustments for provisions, non-current	10.71
	Adjustments for other financial liabilities, current	26.55
	Adjustments for other financial liabilities, non-current	44.78
	Adjustments for unrealised foreign exchange losses gains	0
	Adjustments for dividend income	6294.75
	Adjustments for interest income	193.36
	Adjustments for share-based payments	0
	Adjustments for fair value losses (gains)	-197.54
	Adjustments for undistributed profits of associates	0
	Other adjustments for which cash effects are investing or financing cash flow	0
	Other adjustments to reconcile profit (loss)	0
	Other adjustments for non-cash items	104.6
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0
	Total adjustments for reconcile profit (loss)	-5644.8
	Net cash flows from (used in) operations	9554.11
	Dividends received	0
	Interest paid	0
	Interest received	0
	Income taxes paid (refund)	1450.67
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) operating activities	8103.44
3	Cash flows from used in investing activities	
	Cash flows from losing control of subsidiaries or other businesses	0
	Cash flows used in obtaining control of subsidiaries or other businesses	0
	Other cash receipts from sales of equity or debt instruments of other entities	11510.69
	Other cash payments to acquire equity or debt instruments of other entities	15055.98
	Other cash receipts from sales of interests in joint ventures	0
	Other cash payments to acquire interests in joint ventures	0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0
	Proceeds from sales of property, plant and equipment	0.44
	Purchase of property, plant and equipment	658.15
	Proceeds from sales of investment property	0
	Purchase of investment property	4418.4
	Proceeds from sales of intangible assets	0
	Purchase of intangible assets	0
	Proceeds from sales of intangible assets under development	0
	Purchase of intangible assets under development	0
	Proceeds from sales of goodwill	0
	Purchase of goodwill	0
	Proceeds from biological assets other than bearer plants	0
	Purchase of biological assets other than bearer plants	0
	Proceeds from government grants	0
	Proceeds from sales of other long-term assets	0

	Purchase of other long-term assets	0
	Cash advances and loans made to other parties	0
	Cash receipts from repayment of advances and loans made to other parties	0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts	0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0
	Dividends received	6294.75
	Interest received	193.36
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	-45.37
	Net cash flows from (used in) investing activities	-2178.66
4	Cash flows from used in financing activities	
	Proceeds from changes in ownership interests in subsidiaries	0
	Payments from changes in ownership interests in subsidiaries	0
	Proceeds from issuing shares	0
	Proceeds from issuing other equity instruments	0
	Payments to acquire or redeem entity's shares	0
	Payments of other equity instruments	0
	Proceeds from exercise of stock options	0
	Proceeds from issuing debentures notes bonds etc	0
	Proceeds from borrowings	529.83
	Repayments of borrowings	0
	Payments of lease liabilities	0
	Dividends paid	6117.2
	Interest paid	182.98
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) financing activities	-5770.35
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes	154.43
5	Effect of exchange rate changes on cash and cash equivalents	
	Effect of exchange rate changes on cash and cash equivalents	0
	Net increase (decrease) in cash and cash equivalents	154.43
	Cash and cash equivalents cash flow statement at beginning of period	98.6
	Cash and cash equivalents cash flow statement at end of period	253.03

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)														Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.												
Sr. No.	Details of the party (listed entity / subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the notification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments					Details of the loans, inter-corporate deposits, advances or investments						
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	Notes		
1	ALEMBIC LIMITED	AABCA7950P	NIRAYU LIMITED	AAACN7427K	HOLDING	Sale of goods or services		0.28	No Additional Remarks			0.28	0	0												
2	ALEMBIC LIMITED	AABCA7950P	NIRAYU LIMITED	AAACN7427K	HOLDING	Any other transaction	Security Deposits Received	0	No Additional Remarks			0	0.12	0.12												There were no transactions during the period.
3	ALEMBIC LIMITED	AABCA7950P	NIRAYU LIMITED	AAACN7427K	HOLDING	Any other transaction	Royalty Charges Paid	19.03	No Additional Remarks			19.03	0	0												
4	ALEMBIC LIMITED	AABCA7950P	ALEMBIC CITY LIMITED	AABCA9411F	SUBSIDIARY	Sale of goods or services		1847.41	No Additional Remarks			1847.41	0.02	0												
5	ALEMBIC LIMITED	AABCA7950P	ALEMBIC CITY LIMITED	AABCA9411F	SUBSIDIARY	Any other transaction	Receipt of Commission on Corporate Guarantee given	0.64	No Additional Remarks			0.64	0	0												
6	ALEMBIC LIMITED	AABCA7950P	ALEMBIC CITY LIMITED	AABCA9411F	SUBSIDIARY	Any other transaction	Reimbursement of Expenses received	112.34	No Additional Remarks			112.34	0	0												
7	ALEMBIC LIMITED	AABCA7950P	ALEMBIC CITY LIMITED	AABCA9411F	SUBSIDIARY	Any other transaction	Reimbursement of Expenses Paid	10.22	No Additional Remarks			10.22	0	0												
8	ALEMBIC LIMITED	AABCA7950P	ALEMBIC CITY LIMITED	AABCA9411F	SUBSIDIARY	Any other transaction	Security Deposits Received	0.63	No Additional Remarks			0.63	510.19	510.83												
9	ALEMBIC LIMITED	AABCA7950P	ALEMBIC CITY LIMITED	AABCA9411F	SUBSIDIARY	Investment		0	No Additional Remarks			0	10.07	10.07						Investment	0.00%	NA	Unsecured	NA		There were no transactions during the period.
10	ALEMBIC LIMITED	AABCA7950P	ALEMBIC PHARMACEUTICALS LIMITED	AAICA5591M	ASSOCIATE	Purchase of goods or services		1.13	No Additional Remarks			1.13	0	0												
11	ALEMBIC LIMITED	AABCA7950P	ALEMBIC PHARMACEUTICALS LIMITED	AAICA5591M	ASSOCIATE	Sale of goods or services		1800.9	No Additional Remarks			1800.9	196.96	616.22												
12	ALEMBIC LIMITED	AABCA7950P	ALEMBIC PHARMACEUTICALS LIMITED	AAICA5591M	ASSOCIATE	Any other transaction	Reimbursement of Expenses received	114.25	No Additional Remarks			114.25	0	0												
13	ALEMBIC LIMITED	AABCA7950P	ALEMBIC PHARMACEUTICALS LIMITED	AAICA5591M	ASSOCIATE	Investment		0	No Additional Remarks			0	8665.07	8665.07						Investment	0.00%	NA	Unsecured	NA		There were no transactions during the period.
14	ALEMBIC LIMITED	AABCA7950P	ALEMBIC PHARMACEUTICALS LIMITED	AAICA5591M	ASSOCIATE	Any other transaction	Security Deposits Received	0	No Additional Remarks			0	329.5	329.5												There were no transactions during the period.
15	ALEMBIC LIMITED	AABCA7950P	PAUSHAK LIMITED	AAACD5006G	PROMOTER GROUP	Sale of goods or services		44.6	No Additional Remarks			44.6	0	0												
16	ALEMBIC LIMITED	AABCA7950P	PAUSHAK LIMITED	AAACD5006G	PROMOTER GROUP	Investment		0	No Additional Remarks			0	31544.48	26550.45						Investment	0.00%	NA	Unsecured	NA		1. There are no transactions during the period. 2. Change in opening and closing values reflects variation in market price net of necessary tax adjustments of shares of the listed entity
17	ALEMBIC LIMITED	AABCA7950P	SHRENO LIMITED	AABCA7953Q	PROMOTER GROUP	Any other transaction	Reimbursement of Expenses received	275.69	No Additional Remarks			275.69	282.17	88.07												
18	ALEMBIC LIMITED	AABCA7950P	SHRENO PUBLICATIONS LIMITED	AAFCA4386B	PROMOTER GROUP	Purchase of goods or services		1.3	No Additional Remarks			1.3	0	0												
19	ALEMBIC LIMITED	AABCA7950P	SHRENO PUBLICATIONS LIMITED	AAFCA4386B	PROMOTER GROUP	Sale of goods or services		46.02	No Additional Remarks			46.02	0	0												
20	ALEMBIC LIMITED	AABCA7950P	SHRENO ENGINEERING LIMITED	ABGCS4837F	PROMOTER GROUP	Sale of goods or services		0.28	No Additional Remarks			0.28	0	0												
21	ALEMBIC LIMITED	AABCA7950P	SHRENO ENGINEERING LIMITED	ABGCS4837F	PROMOTER GROUP	Any other transaction	Security Deposits Received	0	No Additional Remarks			0	0.12	0.12												There were no transactions

																						during the period.
22	ALEMBIC LIMITED	AABCA7950P	RAKSHAK SERVICES PRIVATE LIMITED	AACBR002H	PROMOTER GROUP	Purchase of goods or services		5.34	No Additional Remarks			5.34	0	0.81								
23	ALEMBIC LIMITED	AABCA7950P	ALEMBIC CSR FOUNDATION	AAETA764TM	OTHER RELATED PARTY	Any other transaction	CSR Contribution	30.88	No Additional Remarks			30.88	0	0								
24	ALEMBIC LIMITED	AABCA7950P	ALEMBIC LIMITED PROVIDENT FUND	AABTT1558R	OTHER RELATED PARTY	Any other transaction	Post Employment Benefits Plan	109.6	No Additional Remarks			109.6	0	0								
25	ALEMBIC LIMITED	AABCA7950P	ALEMBIC LIMITED GRATUITY FUND	AABA7721M	OTHER RELATED PARTY	Any other transaction	Post Employment Benefits Plan	25	No Additional Remarks			25	0	0								
26	ALEMBIC LIMITED	AABCA7950P	ALEMBIC LIMITED SUPERANNUATION SCHEME	ZZZZZ9999Z	OTHER RELATED PARTY	Any other transaction	Post Employment Benefits Plan	1.66	No Additional Remarks			1.66	0	0								
27	ALEMBIC LIMITED	AABCA7950P	BHAILAL AMIN GENERAL HOSPITAL	AAATB1585B	PROMOTER GROUP	Sale of goods or services		5.32	No Additional Remarks			5.32	0.89	0								
28	ALEMBIC LIMITED	AABCA7950P	BHAILAL AMIN GENERAL HOSPITAL	AAATB1585B	PROMOTER GROUP	Any other transaction	Security Deposits Received	0	No Additional Remarks			0	2.22	2.22								There were no transactions during the period.
29	ALEMBIC LIMITED	AABCA7950P	MALIKA AMIN	ABMPA573OG	PROMOTERS	Remuneration		72	No Additional Remarks			72	0	0								
30	ALEMBIC LIMITED	AABCA7950P	RASESH SHAH	AXHPS8019B	KEY MANAGERIAL PERSONNEL	Remuneration		76.51	No Additional Remarks			76.51	0	0								Remuneration to Key Managerial Personnel is as approved by the Nomination and Remuneration Committee and Board of Directors.
31	ALEMBIC LIMITED	AABCA7950P	KEVAL THAKKAR	AVEPT493ZH	KEY MANAGERIAL PERSONNEL	Remuneration		7.5	No Additional Remarks			7.5	0	0								Remuneration to Key Managerial Personnel is as approved by the Nomination and Remuneration Committee and Board of Directors.
32	ALEMBIC LIMITED	AABCA7950P	ABHIJIT JOSHI	ABBPJ2744E	KEY MANAGERIAL PERSONNEL	Any other transaction	Director Sitting Fees	0.9	No Additional Remarks			0.9	0	0								Sitting fees to Directors is within the limits prescribed under the Companies Act, 2013 and as approved by the Board of Directors.
33	ALEMBIC LIMITED	AABCA7950P	CHIRAYU AMIN	ABMPA5729P	KEY MANAGERIAL PERSONNEL	Any other transaction	Director Sitting Fees	0.8	No Additional Remarks			0.8	0	0								
34	ALEMBIC LIMITED	AABCA7950P	MAYANK AMIN	AALPA9261C	KEY MANAGERIAL PERSONNEL	Any other transaction	Director Sitting Fees	0.85	No Additional Remarks			0.85	0	0								Sitting fees to Directors is within the limits prescribed under the Companies Act, 2013 and as approved by the Board of Directors.
35	ALEMBIC LIMITED	AABCA7950P	RATI DESAI	AAGPS8828Q	KEY MANAGERIAL PERSONNEL	Any other transaction	Director Sitting Fees	1.5	No Additional Remarks			1.5	0	0								Sitting fees to Directors is within the limits prescribed under the Companies Act, 2013 and as approved by the Board of Directors.
36	ALEMBIC LIMITED	AABCA7950P	SAMEER KHERA	ADQPX5503K	KEY MANAGERIAL PERSONNEL	Any other transaction	Director Sitting Fees	1.8	No Additional Remarks			1.8	0	0								Sitting fees to Directors is within the limits prescribed under the Companies Act, 2013 and as approved by the Board of Directors.
37	ALEMBIC LIMITED	AABCA7950P	SAMEER KHERA	ADQPX5503K	KEY MANAGERIAL PERSONNEL	Sale of goods or services		270	No Additional Remarks			270	0	0								
38	ALEMBIC LIMITED	AABCA7950P	UDIT AMIN	ACKPA4056E	KEY MANAGERIAL PERSONNEL	Remuneration		100	No Additional Remarks			100	200	300								
39	ALEMBIC LIMITED	AABCA7950P	UDIT AMIN	ACKPA4056E	KEY MANAGERIAL PERSONNEL	Any other transaction	Director Sitting Fees	1	No Additional Remarks			1	0	0								
40	ALEMBIC LIMITED	AABCA7950P	GIRISH HIRODE	AAHPH3723J	KEY MANAGERIAL PERSONNEL	Any other transaction	Director Sitting Fees	0.9	No Additional Remarks			0.9	0	0								Sitting fees to Directors is within the limits

[illegible]

[illegible]

Details of Impact of Audit Qualification			
Whether results are audited or unaudited		Audited	
Declaration of unmodified opinion or statement on impact of audit qualification		Declaration of unmodified opinion	
Auditor's opinion			
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results		Yes	
	Audit firm's name	Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI	Certificate valid upto
1	CNK & Associates LLP	Yes	31-07-2027